每经AI快讯，8月12日，CRO指数盘中显著回调，现跌2.21%。成分股普遍走弱，成都先导跌4.14%、金 凯生科跌3.84%、阳光诺和跌3.82%、益诺思跌3.31%、奥浦迈跌2.86%领跌。 （文章来源：每日经济新闻） ...

Core Viewpoint - The company *ST Bio is planning to acquire a 51% stake in Hunan Huize Biomedical Technology Co., Ltd. for cash, which will result in Huize becoming a subsidiary of *ST Bio, indicating a significant asset restructuring [2][6]. Group 1: Acquisition Details - The acquisition of Huize Medical, a professional CRO company focused on drug research and clinical evaluation, is expected to enhance *ST Bio's capabilities in the biopharmaceutical sector [5][6]. - Huize Medical generates over 85% of its revenue from clinical evaluation services and has established long-term partnerships with over 300 pharmaceutical companies and research institutions [5]. Group 2: Strategic Benefits - The acquisition is anticipated to extend *ST Bio's biopharmaceutical business, improving its profitability and risk resilience [6]. - The integration of drug research and clinical evaluation services is expected to enhance operational efficiency and create strong synergies [6]. Group 3: Financial Performance - *ST Bio has projected a revenue of 49 million to 52 million yuan for the first half of 2025, representing a year-on-year decline of 7.68% to 13% [7]. - The company expects a net loss attributable to shareholders of 3.5 million to 5 million yuan, an improvement from a loss of 8.39 million yuan in the same period last year [7]. Group 4: Stock Performance - Following a period of stock price decline, *ST Bio's shares were subject to delisting risk warnings starting April 30, 2025, with the stock price dropping to a low of 5.43 yuan per share on April 28 [9]. - Recently, the stock price has rebounded, closing at 12.54 yuan per share as of August 11 [10].

Group 1 - The core point of the article is that *ST Bio (000504) is planning to acquire a 51% stake in Hunan Huize Biomedical Technology Co., Ltd. for cash, which will result in Huize becoming a subsidiary of the company, indicating a significant asset restructuring [2] - Huize is a professional CRO company focused on drug research and clinical evaluation, with over 85% of its revenue coming from clinical evaluation services, and has established long-term partnerships with over 300 pharmaceutical companies and research institutions [5] - The acquisition is expected to enhance *ST Bio's biopharmaceutical business, improve profitability, and increase the company's risk resistance, while also creating synergies through asset integration in clinical research and drug development [5][6] Group 2 - The transaction is anticipated to strengthen the overall growth and profitability of *ST Bio, aligning with the company's strategic development needs and fostering long-term sustainable growth [6] - Following the acquisition, *ST Bio's biopharmaceutical segment will include drug research and clinical evaluation services, enhancing its competitive edge [6] - *ST Bio has previously disclosed a performance forecast, expecting revenue between 49 million to 52 million yuan for the first half of 2025, representing a year-on-year decline of 7.68% to 13% [6]

Core Viewpoint - *ST生物 is planning to acquire a 51% stake in Hunan Huize Biomedical Technology Co., Ltd. for cash, which will make Huize a subsidiary and included in the consolidated financial statements. This transaction is expected to constitute a significant asset restructuring as per the regulations [1] Group 1: Company Overview - Huize Biomedical is a professional CRO company focused on drug research and clinical evaluation, providing services such as pharmaceutical research, clinical trials, and data management statistical analysis [1] - Prior to the acquisition, *ST生物 primarily engaged in two business segments: "biomedical" and "energy conservation and environmental protection," along with the production and sales of other biomedical-related products [1] Group 2: Strategic Intent - The acquisition aims to extend the biomedical segment of *ST生物, enhancing the profitability of its main business and improving its risk resistance capabilities [1] - There is a strong correlation between cell clinical transformation research and drug development, and the asset integration is expected to improve operational efficiency and create significant synergies [1]

Group 1 - The technology sector is recommended as a key focus area until August 2025, driven by the positive trends in the AI industry chain and the current surge in software applications, indicating potential for further growth in domestic computing power and AI applications [1] - The pharmaceutical and biotechnology sectors, particularly innovative drugs, have shown significant price increases, with a long-term positive trend and some companies still having room for valuation recovery compared to their 2020 peaks [1] - The defense and military industry is expected to receive continuous catalysts, with the current fundamentals and confidence in the military sector being better than in historical years, driven more by fundamental factors than calendar effects [1] Group 2 - The Guotai Science and Technology Innovation Index ETF (589630) tracks the Science and Technology Innovation Index (000680), which can experience daily fluctuations of up to 20%, covering nearly 97% of the market capitalization of the Science and Technology Innovation Board [1] - The index emphasizes technological innovation and growth, with a balanced industry distribution aimed at reflecting the overall performance of the Science and Technology Innovation Board market [1] - Investors without stock accounts can consider the Guotai Science and Technology Innovation Board Comprehensive ETF Initiated Link A (023733) and Link C (023734) [1]

Core Viewpoint - Nanhua Biopharmaceutical Co., Ltd. plans to acquire 51% equity of Hunan Huize Biopharmaceutical Technology Co., Ltd. through a cash transaction, aiming to enhance its industry chain and establish Huize as a subsidiary [1] Group 1 - The acquisition is expected to strengthen the synergy between Nanhua and Huize, as Huize focuses on drug research and clinical evaluation, which aligns with Nanhua's business [1] - The transaction does not constitute a related party transaction and is anticipated to be classified as a major asset restructuring [1] - The intention agreement is preliminary, and the specific transaction plan is subject to negotiation, indicating uncertainty regarding the finalization of the deal [1] Group 2 - The acquisition will not involve the issuance of shares or changes in control [1] - The company will fulfill its regulatory approval and information disclosure obligations as required [1] - Investors are reminded to be aware of the associated risks [1]

Market Performance Review - The A-share market experienced a volatile upward trend, reaching new highs, with the CSI 1000 index rising by 2.11%, outperforming other major indices such as the CSI A50 and ChiNext, which increased by 0.64% and 0.49% respectively [12][13] - There was a significant reversal in market style, with cyclical stocks rebounding strongly while the previously resilient consumer style lagged behind [12][13] - All market capitalization styles saw gains, with mid-cap and small-cap indices performing notably better than large-cap indices [12][13] - The performance of core assets and leading growth stocks showed divergence, with the "Ning" combination slightly increasing by 0.07% and the "Mao" index rising by 0.89% [12][13] Industry Analysis - The market's upward movement was primarily driven by event-driven thematic trading, with the defense and military industry leading with a 5.93% increase, followed by significant gains in non-ferrous metals and machinery [4][13] - The defense sector's rise was fueled by China Shipbuilding's announcement on August 5 regarding a stock swap merger with China State Shipbuilding Corporation, which sparked expectations of large-scale restructuring among military-listed companies [4][13] - The only sectors that saw declines were pharmaceuticals, computers, retail, and social services [4][13] Future Outlook and Investment Views - The report emphasizes the importance of both rhythm and direction during the current gap between policy and performance, noting that the recent Central Political Bureau meeting did not indicate large-scale stimulus plans, and the focus will shift more towards demand recovery rather than supply-side reductions [29][30] - The current market rally, which began at the end of June, can be understood as a two-phase structure driven by bank dividends and the transition from "anti-involution" themes, but the potential for further gains may be limited as the appeal of bank dividends diminishes [29][30] - The report suggests a return to growth trading, with individual stock alpha logic taking precedence over industry beta logic, highlighting opportunities for valuation recovery in technology growth sectors such as AI applications, computing power chains, and optical modules [30]

平安证券(香港)研究也指出，当前港股市场仍具有较低估值以及"赚钱效应"下的交易渐趋活跃等优势， 中长期走势仍可保持乐观展望。建议继续关注人工智能、机器人、半导体、工业软件等新质生产力等科 技板块，及政策加力支持的创新医药板块以及具有消费属性的中医药和医疗板块。 本文转载自"腾讯自选股"，智通财经编辑：李佛。 国泰海通发布研报称，尽管6月下旬以来港股相对偏震荡，港股科技相较于创新药等阶段性跑输。但港 股科技、消费类资产与当前AI应用、新消费等产业趋势相关度更高，且基本面更优，相较A股而言仍具 有稀缺性。因此，港股科技、消费、红利等稀缺性资产在宏观偏弱环境下仍具备较强吸引力。预计下半 年港股互联网巨头或将加大AI基础设施领域的资本投入，大模型迭代与AI应用落地进度有望提速。随 着本轮AI浪潮的产业周期向上趋势进一步确认，有望推动相关的港股科技龙头重新跑赢市场。 中信证券研报称，行情的定位决定了主导资金的行为，资金的行为决定了上涨的行业结构及模式。历史 上增量流动性驱动的行情中，领涨行业大都是持续集中，而不是高切低轮动;背后的本质是资金对效率 的追逐，更倾向于高共识品种，而非在低位品种里"蹲变化"。7月的行情演绎也 ...

Group 1 - The stock price of Kanglong Chemical is reported at 28.90 yuan, down 1.83% from the previous trading day, with a trading volume of 1.184 billion yuan [1] - The company operates in the medical services sector as a CRO (Contract Research Organization), providing drug research and development services across various fields including laboratory chemistry, biological sciences, and clinical research services [1] - On August 7, the company stated on an interactive platform that the impact of the US tariffs on its business is limited, as the export of commercial goods constitutes a small portion of its operations [1] Group 2 - On August 7, the net outflow of main funds was 159 million yuan, with a cumulative net outflow of 471 million yuan over the past five trading days [2]

| 603538 | 美诺华 | -5.28 | 13.44 | -7141.76 | | --- | --- | --- | --- | --- | | 000953 | 河化股份 | 1.00 | 21.58 | -6783.63 | | 688222 | 成都先导 | -3.49 | 6.59 | -6676.58 | | 300363 | 博腾股份 | -1.62 | 4.18 | -6054.08 | | 600196 | 复星医药 | -0.98 | 1.29 | -5749.1 1 | | 688185 | 康希诺 | -2.80 | 5.15 | -5649.33 | | 688131 | 皓元医药 | -2.95 | 3.76 | -5426.18 | | 300683 | 海特生物 | -3.97 | 13.76 | -5362.08 | | 688553 | 汇宇制药 | -1.87 | 2.83 | -5128.77 | | 301096 | 百诚医药 | -2.81 | 6.89 | -4796.39 | | 300149 | 睿智医药 | -1.65 | 8.06 | -3859. ...